X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
TN-401 is an investigational adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed for the treatment of ARVC due to disease causing variants in the PKP2 gene.
Lead Product(s): TN-401
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TN-401
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2023
Details:
TN-201 is designed to deliver a fully functional MYBPC3 gene to restore normal levels of myosin-binding protein, which regulates the contraction and relaxation of the heart muscle. It is being investigated for MYBPC3-associated hypertrophic cardiomyopathy.
Lead Product(s): TN-201
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TN-201
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2023
Details:
TN-201 is designed to deliver a fully functional MYBPC3 gene to restore normal levels of myosin-binding protein, which regulates the contraction and relaxation of the heart muscle. It is being investigated for MYBPC3-associated hypertrophic cardiomyopathy.
Lead Product(s): TN-201
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TN-201
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2023
Details:
TN-201 is an adeno-associated virus based investigational gene therapy designed to deliver fully functional MYBPC3 gene to restore its normal levels thereby potentially halt disease progression and reverse the course of genetic HCM after a single treatment.
Lead Product(s): TN-201
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TN-201
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2023
Details:
TN-401 is an AAV-based gene therapy for treatment of genetic ARVC caused by Plakophilin-2 gene mutations can cause severe disease, including enlargement of right ventricle in affected individuals, cardiac dysfunction, significant arrhythmia and sudden cardiac death.
Lead Product(s): TN-401
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TN-401
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 28, 2022
Details:
TN-201 is a potentially curative gene therapy intended to address genetic hypertrophic cardiomyopathy (gHCM) caused by mutations in the Myosin Binding Protein C3 (MYBPC3) gene, that is currently in IND-enabling studies.
Lead Product(s): TN-201
Therapeutic Area: Genetic Disease Product Name: TN-201
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Morgan Stanley
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 21, 2022
Details:
TN-301 (previously named TYA-11631) is a small molecule HDAC6 inhibitor initially being developed by Tenaya for the potential treatment of heart failure with preserved ejection fraction (HFpEF).
Lead Product(s): TN-301
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TN-301
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Piper Sandler
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 17, 2022
Details:
TN-201 is a potentially curative gene therapy intended to address genetic hypertrophic cardiomyopathy (gHCM) caused by mutations in the Myosin Binding Protein C3 (MYBPC3) gene, that is currently in IND-enabling studies.
Lead Product(s): TN-201
Therapeutic Area: Genetic Disease Product Name: TN-201
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Morgan Stanley
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 16, 2022
Details:
TN-301 is Tenaya’s highly specific first-in-class small molecule histone deacetylase (HDAC) 6 inhibitor, initially being developed for the potential treatment of HFpEF.
Lead Product(s): TYA-11631
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TN-301
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2022
Details:
TN-201,uses differentiated approach designed to enable robust expression of MYBPC3 gene in heart, demonstrated significant and durable disease reversal and survival benefit in a relevant murine model after a single dose, as well as tolerability in mice and non-human primates.
Lead Product(s): TN-201
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TN-201
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
